Why the study?
Despite various therapeutic targets in coronary artery disease, non-responsiveness to drugs remains a prevalent issue.
Do single-nucleotide polymorphisms predict drug response in patients with coronary artery disease?
Do single-nucleotide polymorphisms predict drug response in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
This review identifies 161 single-nucleotide polymorphisms that may serve as pharmacogenomic biomarkers for predicting drug response in CAD.
Coronary artery disease (CAD) has a high mortality rate. Despite various therapeutic targets, non-responsiveness to drugs remains a prevalent issue. Pharmacogenomics assesses the way an individual's genetic attributes affect their likely response to drug therapy. Single-nucleotide polymorphisms play a crucial role in determining these outcomes. This review offers an overview of single-nucleotide polymorphisms investigated in clinical studies and their associations with drug response/nonresponse in the treatment of CAD. A total of 104 studies of whole sets of chromosomes and several genes were explored. A total of 161 polymorphisms exhibited associations with drug response/nonresponse in CAD across diverse ethnic populations. This pool can serve as a pharmacogenomic biomarker for predicting response to drug therapy in patients with CAD.
No takes yet. Share an insight, caveat, or question.
Dua et al. (2024) conducted a review in Coronary artery disease. Single-nucleotide polymorphisms was evaluated on Drug response/nonresponse.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: